Alnylam Pharmaceuticals
ALNY
#1097
Rank
โ‚น1.959 T
Marketcap
โ‚น14,626
Share price
-2.02%
Change (1 day)
-64.17%
Change (1 year)
Alnylam Pharmaceuticals Inc. is a biopharmaceutical company focused on the R&D and commercialization of RNA interference (RNAi) therapeutics for genetically defined diseases.

EPS for Alnylam Pharmaceuticals (ALNY)

EPS in 2026 (TTM): โ‚น1,890

According to Alnylam Pharmaceuticals 's latest financial reports the company's current EPS (TTM) is โ‚น1,851. In 2025 the company made an earnings per share (EPS) of โ‚น164.49.

EPS history for Alnylam Pharmaceuticals from 2012 to 2026

Annual EPS

Year EPS Change
2026 (TTM)โ‚น1,8901049.08%
2025โ‚น164.49
2023-โ‚น329.91-62%
2022-โ‚น868.2429.03%
2021-โ‚น672.91-3.36%
2020-โ‚น696.28-8.48%
2019-โ‚น760.767.67%
2018-โ‚น706.5639.74%
2017-โ‚น505.6212.94%
2016-โ‚น447.6738.84%
2015-โ‚น322.44-32.88%
2014-โ‚น480.38259.44%
2013-โ‚น133.65-31.25%
2012-โ‚น194.40

EPS for similar companies or competitors

Company EPS EPS differencediff. Country
Novartis
NVS
โ‚น490.66-73.50%๐Ÿ‡จ๐Ÿ‡ญ Switzerland
Sanofi
SNY
โ‚น185.10-90.00%๐Ÿ‡ซ๐Ÿ‡ท France
Regeneron Pharmaceuticals
REGN
โ‚น4,391 137.15%๐Ÿ‡บ๐Ÿ‡ธ USA
Sarepta Therapeutics
SRPT
-โ‚น245.80-113.28%๐Ÿ‡บ๐Ÿ‡ธ USA
Regulus Therapeutics
RGLS
-โ‚น68.23-103.69%๐Ÿ‡บ๐Ÿ‡ธ USA
OPKO Health
OPK
-โ‚น17.76-100.96%๐Ÿ‡บ๐Ÿ‡ธ USA
Teva Pharmaceutical Industries
TEVA
โ‚น42.06-97.73%๐Ÿ‡ฎ๐Ÿ‡ฑ Israel
Arrowhead Pharmaceuticals
ARWR
-โ‚น311.22-116.81%๐Ÿ‡บ๐Ÿ‡ธ USA